Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
44 Results for "
neuropilin-1
" in MedChemExpress (MCE) Product Catalog:
Products (44)
44 Results for "neuropilin-1" in MCE Product Catalog:
12
12 Publications Verification
Target:
Research Areas:
EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC50 of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2 [1].
7
5
5 Cited Publications
Cat. No.: HY-112151
CAS No.: 2227996-00-9
Target:
Research Areas:
EG01377 is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1), with a Kd of 1.32 μM, and IC50s of both 609 nM for NRP1-a1 and NRP1-b1. EG01377 has antiangiogenic, antimigratory, and antitumor effects [1].
5
5 Cited Publications
Target:
Research Areas:
EG01377 dihydrochloride is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1), with a Kd of 1.32 μM, and IC50s of 609 nM for both NRP1-a1 and NRP1-b1. EG01377 dihydrochloride has antiangiogenic, antimigratory, and antitumor effects [1].
3
3 Cited Publications
Cat. No.: HY-P70147
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: NRP1; Transmembrane Receptor; neuropilin 1; CD304 Antigen; VEGF165R; DKFZp686M1967; NRP; neuropilin; neuropilin-1; BDCA4; CD304; NP1; Vascular Endothelial Cell Growth Factor 165 Receptor
Species:
Human
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P1663A
Target:
Research Areas:
ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF165 binding to NRP-1, used in the research of angiogenesis [1]. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes .
Cat. No.: HY-P99386
CAS No.: 1205533-60-3
Synonyms: MNRP-1685A
Target:
Research Areas:
Cat. No.: HY-172494
Research Areas:
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for agent delivery [1].
Cat. No.: HY-N14827
CAS No.: 151466-15-8
Synonyms: SM-216289
Category:
Target:
Cat. No.: HY-172494A
DSPE-PEG3400-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3400-iRGD can be used for drug delivery [1].
Cat. No.: HY-128446
CAS No.: 1210360-87-4
Target:
Research Areas:
CAY10781 (Compound 11) is an inhibitor of the neuropilin-1 (NRP-1) and VEGF-A interaction. CAY10781 inhibits VEGF-A-induced phosphorylation of VEGFR2 in Catecholamine A-differentiated (CAD) cells [1]< sup>.
Cat. No.: HY-P73312
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: NRP1; Transmembrane Receptor; neuropilin 1; CD304 Antigen; VEGF165R; DKFZp686M1967; NRP; neuropilin; neuropilin-1; BDCA4; CD304; NP1; Vascular Endothelial Cell Growth Factor 165 Receptor
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P702534
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: NRP1; Transmembrane Receptor; neuropilin 1; CD304 Antigen; VEGF165R; DKFZp686M1967; NRP; neuropilin; neuropilin-1; BDCA4; CD304; NP1; Vascular Endothelial Cell Growth Factor 165 Receptor
Species:
Rat
Source:
HEK293
Cat. No.: HY-P73309
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: NRP1; Transmembrane Receptor; neuropilin 1; CD304 Antigen; VEGF165R; DKFZp686M1967; NRP; neuropilin; neuropilin-1; BDCA4; CD304; NP1; Vascular Endothelial Cell Growth Factor 165 Receptor
Species:
Human
Source:
HEK293
Cat. No.: HY-P73310
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: NRP1; Transmembrane Receptor; neuropilin 1; CD304 Antigen; VEGF165R; DKFZp686M1967; NRP; neuropilin; neuropilin-1; BDCA4; CD304; NP1; Vascular Endothelial Cell Growth Factor 165 Receptor
Species:
Human
Source:
HEK293
Cat. No.: HY-172493
DSPE-PEG1000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG1000-iRGD can be used for drug delivery [1].
Cat. No.: HY-172495
DSPE-PEG3000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3000-iRGD can be used for drug delivery [1].
Cat. No.: HY-P70401
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: NRP1; Transmembrane Receptor; neuropilin 1; CD304 Antigen; VEGF165R; DKFZp686M1967; NRP; neuropilin; neuropilin-1; BDCA4; CD304; NP1; Vascular Endothelial Cell Growth Factor 165 Receptor
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P78751
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: NRP1; Transmembrane Receptor; neuropilin 1; CD304 Antigen; VEGF165R; DKFZp686M1967; NRP; neuropilin; neuropilin-1; BDCA4; CD304; NP1; Vascular Endothelial Cell Growth Factor 165 Receptor
Species:
Human
Source:
HEK293
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
